Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe
Giancarlo Agnelli, Ulrich Hoffmann, Pierre Hainaut, Seán Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jiménez, Eva‐Maria Fronk, José Souza, Petra Laeis, Peter Bramlage, Bernd Brüggenjürgen, Pierre Lévy, Alexander T. Cohen (2025). Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe. , DOI: https://doi.org/10.1055/a-2497-4089.
Article169 days agoETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries
Alexander T. Cohen, Ulrich Hoffmann, Pierre Hainaut, Seán Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jiménez, Bernd Brüggenjürgen, Pierre Lévy, Petra Laeis, Eva‐Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Marius Constantin Manu, Paul‐Egbert Reimitz, Peter Bramlage, Giancarlo Agnelli (2020). ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. , 82, DOI: https://doi.org/10.1016/j.ejim.2020.08.014.
Article169 days agoETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months
Marius Constantin Manu, Paul‐Egbert Reimitz, Peter Bramlage, Alexander T. Cohen, Giancarlo Agnelli, Ulrich Hoffmann, Pierre Hainaut, Seán Gaine, Cihan Ay, Michiel Coppens, Marc Schindewolf, David Jiménez, Bernd Brüggenjürgen, Pierre Lévy, Petra Laeis, Eva‐Maria Fronk, Wolfgang Zierhut, Thomas Malzer (2020). ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. , 196, DOI: https://doi.org/10.1016/j.thromres.2020.09.001.
Article169 days agoCorrection to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study
Alexander T. Cohen, Cihan Ay, Pierre Hainaut, Hervé Decousus, Ulrich Hoffmann, Seán Gaine, Michiel Coppens, Pedro Silva Cunha, David Jiménez, Beatrice Amann‐Vesti, Bernd Brüggenjürgen, Pierre Lévy, Julio López Bastida, Éric Vicaut, Petra Laeis, Eva‐Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Peter Bramlage, Giancarlo Agnelli (2018). Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. , 16(1), DOI: https://doi.org/10.1186/s12959-018-0173-5.
Article169 days agoEstimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective
Pierre Lévy, Pierre Lévy, David M. Smadja, David M. Smadja, J Dorey, J Dorey, Mondher Toumi, Mondher Toumi, Anna‐Katharina Meinecke, Anna‐Katharina Meinecke, Kevin Bowrin, Kevin Bowrin, J Brière, J Brière (2019). Estimation of the costs attributable to vitamin K antagonist treatment in patients with non-valvular atrial fibrillation from a French societal perspective.
Preprint48 days ago